PL3672967T3 - Związki azaindolilopirydonu i diazaindolilopirydonu - Google Patents

Związki azaindolilopirydonu i diazaindolilopirydonu

Info

Publication number
PL3672967T3
PL3672967T3 PL18759307T PL18759307T PL3672967T3 PL 3672967 T3 PL3672967 T3 PL 3672967T3 PL 18759307 T PL18759307 T PL 18759307T PL 18759307 T PL18759307 T PL 18759307T PL 3672967 T3 PL3672967 T3 PL 3672967T3
Authority
PL
Poland
Prior art keywords
diazaindolylpyridone
azaindolylpyridone
compounds
diazaindolylpyridone compounds
Prior art date
Application number
PL18759307T
Other languages
English (en)
Polish (pl)
Inventor
Johan LINDSTRÖM
Rickard Forsblom
Fredrik Rahm
Jenny Viklund
Original Assignee
Sprint Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience Ab filed Critical Sprint Bioscience Ab
Publication of PL3672967T3 publication Critical patent/PL3672967T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL18759307T 2017-08-23 2018-08-23 Związki azaindolilopirydonu i diazaindolilopirydonu PL3672967T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187519 2017-08-23
EP18759307.4A EP3672967B1 (en) 2017-08-23 2018-08-23 Azaindolylpyridone and diazaindolylpyridone compounds
PCT/EP2018/072785 WO2019038384A1 (en) 2017-08-23 2018-08-23 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS

Publications (1)

Publication Number Publication Date
PL3672967T3 true PL3672967T3 (pl) 2022-01-31

Family

ID=59686871

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18759307T PL3672967T3 (pl) 2017-08-23 2018-08-23 Związki azaindolilopirydonu i diazaindolilopirydonu

Country Status (20)

Country Link
US (2) US11498919B2 (https=)
EP (2) EP3672967B1 (https=)
JP (2) JP7199738B2 (https=)
KR (1) KR102731945B1 (https=)
CN (3) CN116589461A (https=)
AU (1) AU2018321135B2 (https=)
CY (1) CY1124818T1 (https=)
DK (1) DK3672967T3 (https=)
ES (1) ES2902346T3 (https=)
HR (1) HRP20211999T1 (https=)
HU (1) HUE057818T2 (https=)
IL (3) IL302355A (https=)
LT (1) LT3672967T (https=)
PL (1) PL3672967T3 (https=)
PT (1) PT3672967T (https=)
RS (1) RS62785B1 (https=)
SI (1) SI3672967T1 (https=)
SM (1) SMT202100718T1 (https=)
TW (2) TW202325708A (https=)
WO (1) WO2019038384A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7199738B2 (ja) * 2017-08-23 2023-01-06 スプリント バイオサイエンス アクティエボラーグ アザインドリルピリドンおよびジアザインドリルピリドン化合物
CA3200038A1 (en) * 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Anti-viral activity of vps34 inhibitors
WO2022115562A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154024B (it) * 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
CN102143746A (zh) * 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
CA2795422A1 (en) * 2010-04-19 2011-10-27 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
AU2011346567A1 (en) 2010-12-21 2013-07-25 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
DK2655375T3 (en) 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
CN103450152B (zh) 2012-06-04 2015-11-18 济南海乐医药技术开发有限公司 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
AU2015206652A1 (en) 2014-01-14 2016-08-04 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2015108881A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
AU2017219846B2 (en) 2016-02-19 2021-05-13 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
DK3416957T3 (da) 2016-02-19 2020-09-21 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
JP7199738B2 (ja) * 2017-08-23 2023-01-06 スプリント バイオサイエンス アクティエボラーグ アザインドリルピリドンおよびジアザインドリルピリドン化合物

Also Published As

Publication number Publication date
ES2902346T3 (es) 2022-03-28
CY1124818T1 (el) 2022-11-25
CA3072861A1 (en) 2019-02-28
RU2020110503A (ru) 2021-09-23
SI3672967T1 (sl) 2022-04-29
TWI785101B (zh) 2022-12-01
LT3672967T (lt) 2022-01-10
AU2018321135A1 (en) 2020-04-02
RU2020110503A3 (https=) 2021-12-27
RS62785B1 (sr) 2022-01-31
EP3672967A1 (en) 2020-07-01
WO2019038384A1 (en) 2019-02-28
US20210122745A1 (en) 2021-04-29
SMT202100718T1 (it) 2022-03-21
EP3672967B1 (en) 2021-10-06
CN111247144B (zh) 2023-04-28
KR102731945B1 (ko) 2024-11-18
IL272792B (en) 2022-06-01
IL292482B1 (en) 2023-05-01
DK3672967T3 (da) 2022-01-10
IL272792A (en) 2020-04-30
JP7199738B2 (ja) 2023-01-06
CN116589462A (zh) 2023-08-15
PT3672967T (pt) 2021-12-28
AU2018321135B2 (en) 2023-11-23
IL292482A (en) 2022-06-01
CN116589461A (zh) 2023-08-15
TW201912643A (zh) 2019-04-01
HRP20211999T1 (hr) 2022-04-01
CN111247144A (zh) 2020-06-05
TW202325708A (zh) 2023-07-01
JP2020531487A (ja) 2020-11-05
HUE057818T2 (hu) 2022-06-28
US20230322772A1 (en) 2023-10-12
IL302355A (en) 2023-06-01
JP2023021277A (ja) 2023-02-10
US11498919B2 (en) 2022-11-15
KR20200043412A (ko) 2020-04-27
EP4001278A1 (en) 2022-05-25
IL292482B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
IL273236A (en) Pyrazolopyrimidine compounds and their uses
GB201708652D0 (en) Novel compounds and uses
GB201714745D0 (en) New compounds and uses
IL273493A (en) Modified CAR-T
SG11201706029VA (en) Anti-senescence compounds and uses thereof
IL272808B (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
GB201714734D0 (en) New compounds and uses
GB201714740D0 (en) New compounds and uses
ZA201705456B (en) Benzoxaborole compounds and uses thereof
GB201616439D0 (en) Compounds and uses
GB201504763D0 (en) Compounds and uses
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201714736D0 (en) New compounds and uses
GB201712110D0 (en) New compounds and uses
GB201700404D0 (en) Compounds and composistions
IL253459A0 (en) Isoergoline compounds and their uses
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
GB201614224D0 (en) Compounds and uses thereof
IL265617B (en) 1-phenylpropanone compounds and their use
GB201720092D0 (en) New Compounds and uses
GB201719327D0 (en) New compounds and uses
GB201719233D0 (en) New compounds and uses
GB201719043D0 (en) Methods and compounds
GB201714743D0 (en) New compounds and uses
GB201720943D0 (en) New processes and compounds